Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes

Molecular Carcinogenesis

Volumn 47, Issue 1, 2008, Pages 56-65

  Birch, Ashley H ^a   Quinn, Michael C J ^a   Filali Mouhim, Ali ^b   Provencher, Diane M ^b,c   Mes Masson, Anne Marie ^b,c   Tonin, Patricia N ^a,d,e  

^a MCGILL UNIVERSITY   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Chromosome 3; Microarray; Ovarian cancer

Indexed keywords

ARTICLE; CARCINOGENESIS; CELL LINE; CHROMOSOME 3; CORRELATION ANALYSIS; EPITHELIUM CELL; FEMALE; GBE1 GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE LOCUS; GENE SEQUENCE; HEG1 GENE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; OVARY CANCER; PRIORITY JOURNAL; RIS1 GENE; SEQUENCE ANALYSIS; TRANSCRIPTOMICS; CHROMOSOME ABERRATION; CHROMOSOME MAP; CULTURE TECHNIQUE; CYTOLOGY; GENETIC TRANSCRIPTION; GENETICS; ISOLATION AND PURIFICATION; OVARY; OVARY TUMOR; TUMOR CELL LINE;

DNA;

CELL CULTURE TECHNIQUES; CELL LINE; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 3; DNA, NEOPLASM; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; OVARY; TRANSCRIPTION, GENETIC;

EID: 38349074976     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20361     Document Type: Article

References (77)

1. Bernardini M, Weberpals J, Squire JA. The use of cytogenetics in understanding ovarian cancer. Biomed Pharmacother 2004;58:17-23.
2. Mertens F, Johansson B, Hoglund M, Mitelman F. Chromosomal imbalance maps of malignant solid tumors: A cytogenetic survey of 3185 neoplasms. Cancer Res 1997; 57:2765-2780.
3. Pejovic T, Heim S, Mandahl N, et al. Chromosome aberrations in 35 primary ovarian carcinomas. Genes Chromosomes Cancer 1992;4:58-68.
4. Whang-Peng J, Knutsen T, Douglass EC, et al. Cytogenetic studies in ovarian cancer. Cancer Genet Cytogenet 1984;11:91-106.
5. Yonescu R, Currie JL, Hedrick L, Campbell J, Griffin CA. Chromosome abnormalities in primary endometrioid ovarian carcinoma. Cancer Genet Cytogenet 1996;87:167-171.
6. Hoglund M, Gisselsson D, Mandahl N, et al. Multivariate analyses of genomic imbalances in solid tumors reveal distinct and converging pathways of karyotypic evolution. Genes Chromosomes Cancer 2001;31:156-171.
7. Simon R, Desper R, Papadimitriou CH, et al. Chromosome abnormalities in ovarian adenocarcinoma: III. Using breakpoint data to infer and test mathematical models for oncogenesis. Genes Chromosomes Cancer 2000;28:106-120.
8. Taetle R, Aickin M, Panda L, et al. Chromosome abnormalities in ovarian adenocarcinoma: II. Prognostic impact of nonrandom chromosome abnormalities in 244 cases. Genes Chromosomes Cancer 1999;25:46-52.
9. Taetle R, Aickin M, Yang JM, et al. Chromosome abnormalities in ovarian adenocarcinoma: I. Nonrandom chromosome abnormalities from 244 cases. Genes Chromosomes Cancer 1999;25:290-300.
10. Dodson MK, Hartmann LC, Cliby WA, et al. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas. Cancer Res 1993;53:4456-4460.
11. Ehlen T, Dubeau L. Loss of heterozygosity on chromosomal segments 3p, 6q and 11p in human ovarian carcinomas. Oncogene 1990;5:219-223.
12. Fullwood P, Marchini S, Rader JS, et al. Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer. Cancer Res 1999;59:4662-4667.
13. Lounis H, Mes-Masson AM, Dion F, et al. Mapping of chromosome 3p deletions in human epithelial ovarian tumors. Oncogene 1998;17:2359-2365.
14. Petursdottir TE, Thorsteinsdottir U, Jonasson JG, et al. Interstitial deletions including chromosome 3 common eliminated region 1 (C3CER1) prevail in human solid tumors from 10 different tissues. Genes Chromosomes Cancer 2004;41:232-242.
15. Zheng JP, Robinson WR, Ehlen T, Yu MC, Dubeau L. Distinction of low grade from high grade human ovarian carcinomas on the basis of losses of heterozygosity on chromosomes 3, 6,and 11 and HER-2/neu gene amplification. Cancer Res 1991;51:4045-4051.
16. Rimessi P, Gualandi F, Morelli C, et al. Transfer of human chromosome 3 to an ovarian carcinoma cell line identifies three regions on 3p involved in ovarian cancer. Oncogene 1994;9:3467-3474.
17. Cody NA, Ouellet V, Manderson EN, et al. Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene 2007;26:618-632.
18. Tse C, Xiang RH, Bracht T, Naylor SL. Human Semaphorin 3B (SEMA3B) located at chromosome 3p21.3 suppresses tumor formation in an adenocarcinoma cell line. Cancer Res 2002;62:542-546.
19. Xiang R, Davalos AR, Hensel CH, Zhou XJ, Tse C. Naylor SL. Semaphorin 3F gene from human 3p21. 3 suppresses tumor formation in nude mice. Cancer Res 2002;62:2637-2643.
20. Wang L, Darling J, Zhang JS, et al. Loss of expression of the DRR 1 gene at chromosomal segment 3p21.1 in renal cell carcinoma. Genes Chromosomes Cancer 2000;27: 1-10.
21. Agathanggelou A, Honorio S, Macartney DP, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 2001;20: 1509-1518.
22. Imura M, Yamashita S, Cai LY, et al. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines. Cancer Lett 2006;241:213-220.
23. Kwong J, Lee JY, Wong KK, et al. Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia 2006;8:268-278.
24. Dallol A, Forgacs E, Martinez A, et al. Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTT1 (ROBO1) in human cancers. Oncogene 2002;21:3020-3028.
25. Huebner K. Tumor suppressors on 3p: A neoclassic quartet. Proc Natl Acad Sci USA 2001;98:14763-14765.
26. Imreh S, Klein G, Zabarovsky ER. Search for unknown tumor-antagonizing genes. Genes Chromosomes Cancer 2003;38:307-321.
27. Xian J, Clark KJ, Fordham R, Pannell R, Rabbitts TH, Rabbitts PH. Inadequate lung development and bronchial hyperplasia in mice with a targeted deletion in the Dutt1/Robo1 gene. Proc Natl Acad Sci USA 2001;98:15062-15066.
28. Zabarovsky ER, Lerman MI, Minna JD. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 2002;21:6915-6935.
29. Dent J, Hall GD, Wilkinson N, et al. Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation. Br J Cancer 2003;88:1578-1583.
30. Kiechle M, Jacobsen A, Schwarz-Boeger U, Hedderich J, Pfisterer J, Arnold N. Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. Cancer 2001; 91:534-540.
31. Patael-Karasik Y, Daniely M, Gotlieb WH, et al. Comparative genomic hybridization in inherited and sporadic ovarian tumors in Israel. Cancer Genet Cytogenet 2000;121:26-32.
32. Staebler A, Heselmeyer-Haddad K, Bell K, et al. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas. Hum Pathol 2002; 33:47-59.
33. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102.
34. Sunde JS, Donninger H, Wu K, et al. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-{beta} signaling in ovarian cancer. Cancer Res 2006;66:8404-8412.
35. Guan XY, Fung JM, Ma NF, et al. Oncogenic role of eIF-5A2 in the development of ovarian cancer. Cancer Res 2004;64: 4197-4200.
36. Sugita M, Tanaka N, Davidson S, et al. Molecular definition of a small amplification domain within 3q26 in tumors of cervix, ovary, and lung. Cancer Genet Cytogenet 2000;117:9-18.
37. Park TW, Riethdorf S, Riethdorf L, Loning T, Janicke F. Differential telomerase activity, expression of the telomerase catalytic sub-unit and telomerase-RNA in ovarian tumors. Int J Cancer 1999;84:426-431.
38. Manderson EN, Mes-Masson AM, Novak J, et al. Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays. Genome Res 2002;12:112-121.
39. Provencher DM, Lounis H, Champoux L, et al. Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim 2000;36:357-361.
40. Tonin PN, Hudson TJ, Rodier F, et al. Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene 2001;20:6617-6626.
41. Arcand SL, Mes-Masson AM, Provencher D, Hudson TJ, Tonin PN. Gene expression microarray analysis and genome data bases facilitate the characterization of a chromosome 22 derived homogeneously staining region. Mol Carcinog 2004; 41:17-38.
42. Benoit MH, Hudson TJ, Maire G, et al. Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines. Int J Oncol 2007;30:5-17.
43. Presneau N, Mes-Masson AM, Ge B, Provencher D, Hudson TJ, Tonin PN. Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines. Oncogene 2003;22: 1568-1579.
44. Kruk PA, Maines-Bandiera SL, Auersperg N. A simplified method to culture human ovarian surface epithelium. Lab Invest 1990;63:132-136.
45. Lounis H, Provencher D, Godbout C, Fink D, Milot MJ, Mes-Masson AM. Primary cultures of normal and tumoral human ovarian epithelium: A powerful tool for basic molecular studies. Exp Cell Res 1994;215:303-309.
46. Dion F, Mes-Masson AM, Seymour RJ, Provencher D, Tonin PN. Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers. Oncogene 2000;19:1466-1472.
47. Novak JP, Sladek R, Hudson TJ. Characterization of variability in large-scale gene expression data: Implications for study design. Genomics 2002;79:104-113.
48. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
49. Benjamini Y, Yekutieli D. Quantitative trait Loci analysis using the false discovery rate. Genetics 2005;171:783-790.
50. Presneau N, Dewar K, Forgetta V, Provencher D, Mes-Masson AM, Tonin PN. Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1-q25.2. Mol Carcinog 2005;43:141-154.
51. Grunt TW, Puckmair K, Tomek K, Kainz B, Gaiger A. An EGF receptor inhibitor induces RAR-beta expression in breast and ovarian cancer cells. Biochem Biophys Res Commun 2005; 329:1253-1259.
52. Makarla PB, Saboorian MH, Ashfaq R, et al. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 2005;11:5365-5369.
53. Mok SC, Wong KK, Chan RK, et al. Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol Oncol 1994;52:247-252.
54. Chan A, Wong F, Arumanayagam M. Serum ultrafiltrable copper, total copper and caeruloplasmin concentrations in gynaecological carcinomas. Ann Clin Biochem 1993;30: 545-549.
55. Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. Coordinately up-regulated genes in ovarian cancer. Cancer Res 2001;61:3869-3876.
56. Lancaster JM, Sayer R, Blanchette C, et al. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival. Clin Cancer Res 2003;9:762-766.
57. Lee CM, Lo HW, Shao RP, et al. Selective activation of ceruloplasmin promoter in ovarian tumors: Potential use for gene therapy. Cancer Res 2004;64:1788-1793.
58. Pulay T, Csomor S, Kovacs I, Szarka G, Somos P. Changes of serum proteins in patients with malignant gynaecological tumours. Acta Chir Hung 1988;29:305-314.
59. Horiuchi A, Imai T, Wang C, et al. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 2003;83: 861-870.
60. Brooks DJ, Woodward S, Thompson FH, et al. Expression of the zinc finger gene EVI-1 in ovarian and other cancers. Br J Cancer 1996;74:1518-1525.
61. Ouellet V, Provencher DM, Maugard CM, et al. Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 2005;24:4672-4687.
62. Zorn KK, Jazaeri AA, Awtrey CS, et al. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res 2003;9:4811-4818.
63. Barradas M, Gonos ES, Zebedee Z, et al. Identification of a candidate tumor-suppressor gene specifically activated during Ras-induced senescence. Exp Cell Res 2002;273: 127-137.
64. Sussan TE, Pletcher MT, Murakami Y, Reeves RH. Tumor suppressor in lung cancer 1 (TSLC1) alters tumorigenic growth properties and gene expression. Mol Cancer 2005; 4:28.
65. Silva J, Silva JM, Barradas M, et al. Analysis of the candidate tumor suppressor Ris-1 in primary human breast carcinomas. Mutat Res 2006;594:78-85.
66. Verlinden I, Janssens J, Raus J, Michiels L. Microdissection and SAGE as a combined tool to reveal gene expression in ductal carcinoma in situ of the breast. Mol Carcinog 2004;41:197-206.
67. Zirn B, Samans B, Wittmann S, et al. Target genes of the WNT/beta-catenin pathway in Wilms tumors. Genes Chromosomes Cancer 2006;45:565-574.
68. Iglesias D, Fernandez-Peralta AM, Nejda N, et al. RIS1, a gene with trinucleotide repeats, is a target in the mutator pathway of colorectal carcinogenesis. Cancer Genet Cytogenet 2006; 167:138-144.
69. Nieto M, Barradas M, Criado LM, Flores JM, Serrano M, Llano E. Normal cellular senescence and cancer susceptibility in mice genetically deficient in Ras-induced senescence-1 (Ris1). Oncogene 2007;26:1673-1680.
70. Lombaerts M, van Wezel T, Philippo K, et al. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer 2006;94:661-671.
71. Mably JD, Mohideen MA, Burns CG, Chen JN, Fishman MC. Heart of glass regulates the concentric growth of the heart in zebrafish. Curr Biol 2003;13:2138-2147.
72. Lang T, Hansson GC, Samuelsson T. An inventory of mucin genes in the chicken genome shows that the mucin domain of Muc13 is encoded by multiple exons and that ovomucin is part of a locus of related gel-forming mucins. BMC Genomics 2006;7:197.
73. Hollingsworth MA, Swanson BJ. Mucins in cancer: Protection and control of the cell surface. Nat Rev Cancer 2004;4: 45-60.
74. Chauhan SC, Singh AP, Ruiz F, et al. Aberrant expression of MUC4 in ovarian carcinoma: Diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod Pathol 2006;19:1386-1394.
75. Taylor-Papadimitriou J, Burchell J, Miles DW. Dalziel M. MUC1 and cancer. Biochim Biophys Acta 1999;1455:301-313.
76. Haura EB, Zheng Z, Song L, Cantor A, Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 2005;11:8288-8294.
77. Presneau N, Manderson EN, Tonin PN. The quest for a tumor suppressor gene phenotype. Curr Mol Med 2003;3:605-629.